Seroatlas · Human Serome Atlas

ADGRE2

Adhesion G protein-coupled receptor E2

Also known as: AGRE2_HUMAN, CD312, EMR2

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
Q9UHX3
Gene
ADGRE2
Ensembl
ENSG00000127507
Chromosome
19
Canonical length
823 aa
Protein class
CD markers, Disease related genes, G-protein coupled receptors, Human disease related genes, Potential drug targets, Predicted membrane proteins
Subcellular location
Vesicles,Cytosol

OverviewNCBI Gene

This gene encodes a member of the class B seven-span transmembrane (TM7) subfamily of G-protein coupled receptors. These proteins are characterized by an extended extracellular region with a variable number of N-terminal epidermal growth factor-like domains coupled to a TM7 domain via a mucin-like spacer domain. The encoded protein is expressed mainly in myeloid cells where it promotes cell-cell adhesion through interaction with chondroitin sulfate chains. This gene is situated in a cluster of related genes on chromosome 19. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene. [provided by RefSeq, Aug 2012]

Canonical amino-acid sequenceUniProt

823 residues, UniProt reviewed canonical sequence.

>Q9UHX3|ADGRE2
     1  MGGRVFLVFL AFCVWLTLPG AETQDSRGCA RWCPQDSSCV NATACRCNPG FSSFSEIITT
    61  PMETCDDINE CATLSKVSCG KFSDCWNTEG SYDCVCSPGY EPVSGAKTFK NESENTCQDV
   121  DECQQNPRLC KSYGTCVNTL GSYTCQCLPG FKLKPEDPKL CTDVNECTSG QNPCHSSTHC
   181  LNNVGSYQCR CRPGWQPIPG SPNGPNNTVC EDVDECSSGQ HQCDSSTVCF NTVGSYSCRC
   241  RPGWKPRHGI PNNQKDTVCE DMTFSTWTPP PGVHSQTLSR FFDKVQDLGR DYKPGLANNT
   301  IQSILQALDE LLEAPGDLET LPRLQQHCVA SHLLDGLEDV LRGLSKNLSN GLLNFSYPAG
   361  TELSLEVQKQ VDRSVTLRQN QAVMQLDWNQ AQKSGDPGPS VVGLVSIPGM GKLLAEAPLV
   421  LEPEKQMLLH ETHQGLLQDG SPILLSDVIS AFLSNNDTQN LSSPVTFTFS HRSVIPRQKV
   481  LCVFWEHGQN GCGHWATTGC STIGTRDTST ICRCTHLSSF AVLMAHYDVQ EEDPVLTVIT
   541  YMGLSVSLLC LLLAALTFLL CKAIQNTSTS LHLQLSLCLF LAHLLFLVAI DQTGHKVLCS
   601  IIAGTLHYLY LATLTWMLLE ALYLFLTARN LTVVNYSSIN RFMKKLMFPV GYGVPAVTVA
   661  ISAASRPHLY GTPSRCWLQP EKGFIWGFLG PVCAIFSVNL VLFLVTLWIL KNRLSSLNSE
   721  VSTLRNTRML AFKATAQLFI LGCTWCLGIL QVGPAARVMA YLFTIINSLQ GVFIFLVYCL
   781  LSQQVREQYG KWSKGIRKLK TESEMHTLSS SAKADTSKPS TVN

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against ADGRE2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Cell surface
Secreted
No
Transmembrane segments
7
Mean surface accessibility (rSASA)
0.32
Highest tissue expression
18 nTPM

Expression across tissuesHPA

Tissue

  • appendix: 18 nTPM
  • spleen: 15 nTPM
  • bone marrow: 6.5 nTPM
  • urinary bladder: 5 nTPM
  • adipose tissue: 4.6 nTPM
  • lung: 4 nTPM

Single-cell type

  • neutrophils: 1,737 nCPM
  • monocytes: 415 nCPM
  • mast cells: 297 nCPM
  • macrophages: 182 nCPM
  • kupffer cells: 148 nCPM
  • thymocytes: 124 nCPM

Immune cell

  • non-classical monocyte: 90 nTPM
  • eosinophil: 75 nTPM
  • basophil: 70 nTPM
  • neutrophil: 56 nTPM
  • intermediate monocyte: 47 nTPM
  • classical monocyte: 14 nTPM

Brain region

  • medulla oblongata: 9.7 nTPM
  • cerebral cortex: 9.2 nTPM
  • white matter: 9.2 nTPM
  • pons: 9 nTPM
  • thalamus: 8.6 nTPM
  • midbrain: 7.9 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about ADGRE2.

Disease | AllUniProt

Conditions ADGRE2 is implicated in, by any mechanism.

Disease | GeneticClinVar

1 pathogenic / likely-pathogenic of 672 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

  • Vibratory urticaria

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
1.25
gnomAD pLI
0
DepMap mean gene effect
-0.16
DepMap dependency class
selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of ADGRE2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads ADGRE2 as an antibody target. Whether an autoantibody or antibody against ADGRE2 could matter depends on whether native ADGRE2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

ADGRE2 is annotated at the cell surface, where native ADGRE2 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label ADGRE2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/ADGRE2. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

© 2026 · Seroatlas, Discover Oregon LLC · Terms of use

Loading the interactive Seroatlas protein explorer...